

## PromarkerD – Proteomics International's Ground-breaking Predictive Test for Diagnosis of Diabetic Kidney Disease

Proteomics International (PI) is pleased to announce that it has produced and validated a predictive test for the diagnosis of diabetic kidney disease (DKD). The test, called PromarkerD, is the world's first proteomics-derived predictive (prognostic) test for the diagnosis of DKD, and represents a global breakthrough in the diagnosis and treatment of the disease. There is currently no available test for predicting the onset of DKD.



[Media release 9 June](#)

The test was developed using PI's world-leading proprietary proteomics platform to measure specific biomarkers (biological signatures) in the blood of patients with diabetes to determine the likelihood of those patients contracting DKD. Specifically, PromarkerD simultaneously measures a panel of 2-6 proteins to determine the patient's disease state.

Applying its mass spectrometry-based proteomics technology, the Company has developed a deeper understanding of DKD beyond classical pathology, by comparing the differences in the protein makeup of people with and without the disease.

## Proteomics International Secures Major Analytical Services Contract in Biosimilars Market

PI has secured a significant contract with a Middle East based biopharmaceutical company. This company is a major producer of biosimilars (generic drugs) across a wide spectrum of treatment targets, including blood disorders and multiple types of cancers. PI will utilise its state-of-the-art proteomics technology platform to provide analysis of the company's biosimilar drugs to prove comparability of its drug against the patented version and to provide quality control of its different batches.

[Media release 28 April](#)

## Proteomics International Laboratories Goes Public 16<sup>th</sup> April 2015

Emerging life science company Proteomics International Laboratories Ltd (PILL) successfully closed its IPO after raising \$3.1 million. On listing, the Company has a tight capital structure, with 50.6 million shares on issue, and a market capitalisation of \$10.1 million. The strong level of investor interest in the IPO is a reflection of the major growth potential of PIQ's world leading proprietary technology platform in the area of proteomics – the industrial scale study of the structure and function of proteins. [Media release 16 April](#)



**PIQ**

PROTEOMICS INTERNATIONAL LABORATORIES LTD

## Proteomics International Secures Major Analytical Services Contract with the a2 Milk Company

The a2 Milk Company is the manufacturer of the high quality a2 Milk branded dairy products. Under the initial contract period of 12 months, PI will specifically test for the presence of beta casein variant proteins in a2 Milk's products on a daily basis to validate protein composition for quality control purposes. [Media release 23 April](#)

### Contact us:

Website: [Proteomics International](http://Proteomics International)  
E-mail: [info@proteomics.com.au](mailto:info@proteomics.com.au)

### Agents:

Japan – Leave a Nest Co. Ltd – [info@leaveanest.com](mailto:info@leaveanest.com)  
China & Hong Kong – Asia Bio Channel Limited – [bcoissac@asiabiochannel.com](mailto:bcoissac@asiabiochannel.com)  
India – KAN-THT Pvt Ltd – [bioservices@kan-tht.com](mailto:bioservices@kan-tht.com)  
Malaysia/ Indonesia/ Thailand – First BASE Laboratories S/B – [peptide-my@base-asia.com](mailto:peptide-my@base-asia.com) / [peptide@base-asia.com](mailto:peptide@base-asia.com)  
Singapore – Axil Scientific Pte Ltd – [peptide@axilscientific.com](mailto:peptide@axilscientific.com)